Cristina A. Muller

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 95 publications

Single Photon Emission Computed Tomography Tracer.

Single Photon Emission Computed Tomography Tracer.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Published: May 18, 2026

Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide.

Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide.

Journal: Journal of structural biology: X
Published: February 19, 2026

Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer.

Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer.

Journal: EJNMMI research
Published: July 14, 2025

Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer.

Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging
Published: July 03, 2025

Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 17, 2025

Design and Preclinical Evaluation of Novel uPAR-Targeting Radiopeptides Modified with an Albumin-Binding Entity.

Design and Preclinical Evaluation of Novel uPAR-Targeting Radiopeptides Modified with an Albumin-Binding Entity.

Journal: Molecular pharmaceutics
Published: May 06, 2025

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Journal: EJNMMI physics
Published: April 29, 2025

Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis.

Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis.

Journal: European journal of nuclear medicine and molecular imaging
Published: January 27, 2025

Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.

Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.

Journal: EJNMMI research
Published: November 20, 2024

First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 16, 2024

Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.

Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging
Published: September 23, 2024

Theranostics - a sure cure for cancer after 100 years?

Theranostics - a sure cure for cancer after 100 years?

Journal: Theranostics
Published: March 27, 2024
Showing 1-12 of 95

Last Updated: 09/26/2026